

SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND ANXIETY

BRANDON BROCK, DNP, DC, NP-C, MSN, APRN, DACNB, FICC







The FDA has not evaluated the statements or claims made in this presentation. This is not intended to diagnose, treat, or prevent any disease and does not replace an evaluation by a qualified medical professional. This is educational only.

Any perceived claims made during this presentation about Bio-Botanical Research, Inc. products are based on my professional clinical experience and are not made on behalf of the company.






CAUSATION, SYMPTOMS, SIGNS



ORDER OF PATHOLOGY AND PRIORITIES

- Complexity and causation
- Symptomatology
- Breaching the gut barrier
- Breaching multiple barriers
- Motility changes
- Pathway to the brain
- Pathway to brain destruction
- Brain: healthy vs. unhealthy
- Gut inflammation stress hormones brain
- Prolonged neurological inflammation and HPA axis
- Eventual transmitter changes and altered psychological function
- Cortical failure and limbic preservation
- Treatment ideas

THE BIGGER PICTURE



SIBO TO THE BRAIN **COMPLEXITY OF CAUSATION**

Learn:


Exam

Gut

Brain

Meds

Common Causes of SIBO Checklist



Steven Sandberg-Lewis 2014, 2016, 2017

SIBO AND SYMPTOMATOLOGY

Hydrogen (H₂) and methane (CH₄) are exclusively produced by microbial metabolism and are exhaled on the breath.

The North American consensus defines a rise in $H_2 \ge 20$ parts per million (ppm) from baseline within 90 min of substrate ingestion as positive for the H_2 breath test.

A CH_4 level \geq ten ppm at any time is defined as positive for the CH_4 breath test.

SIBO is associated with a myriad of causation and symptoms:

Hydrogen

• Mainly diarrhea

Hydrogen Sulfide

 Diarrhea, body pains, food sensitivities

Methane

Mainly constipation

Common symptoms

- Bloating
- Abdominal pain
- Nausea
- Constipation
- Diarrhea

HYDROGEN

Indicative of:

Small Intestinal Bacterial Overgrowth (SIBO)

Predicts:


Bloating and Diarrhea

METHANE

Indicative of:

Intestinal Methanogenic Overgrowth (IMO)

Predicts:
Constipation






GOING FROM INTESTINES TO A SYSTEMIC ISSUE



SLOWING MOTILITY

Proposed Model for Pathogenesis of Irritable Bowel Syndrome



BREACHING THE BARRIERS




Chart creation: Dr. Brandon Brock 2023

BREACHING THE WALLS






FIGURE 3 | Mechanisms through which SIBO affects the host. The dotted arrows indicate increased intestinal permeability. * Includes vitamin A, D, E, and vitamin B 12. Vitamin K is synthesised by the gut microbiota, and thus its deficiency in this context is very unlikely. BA, bile acids; UBA, unconjugated bile acids; LPS, liposaccharides. Created with BioRender.com.

BREACHING MULTIPLE WALLS








GETTING TO THE BRAIN



IT WILL EVENTUALLY GET THERE







Chart creation: Dr. Brandon Brock 2023

HEALTHY AND UNHEALTHY



INFLAMMATION AND STRESS





Fig. 1. Diagrammatic representation of the mast cell and gut-microbiota showing the proposed bidirectional interaction. MCs and gut-microbiota influences neural, neuroimmune, enteroendocrine, serotonin and tryptophan signaling pathways, which plays a significant role in neuroinflammatory mechanisms, neuroimmune responses, and neurobiological functions. Under stress and environmental stimuli may activate MCs and alter gut-microbiota composition lead to release of neuromediators, inflammatory cytokines, chemokines and histamine. These mediators may induce increased permeability of the intestinal gut microbiota and disrupt BBB, and Revised figures Click here to access/download;Figure;Revised figure-pdf activated microglia, astrocytes cells enhancing neuroinflammation result in neurodegenerative diseases. (MCs: Mast cells, GBB: Gut-blood barrier, BBB: Blood-brain barrier).

NEUROGENESIS AND DEGENERATION






CORTICAL AND CHANGES IN THE CNS



STRESS AND TRANSMITTERS




- Exposure to chronic stressors and threats drives adrenocorticotropic hormone (ACTH), cortisol release, and increased sympathetic nervous system activity (SNS).
- SNS activation of NF-κB activity in immune cells increases expression of pro-inflammatory cytokines (e.g., IL-1,IL-6, TNF, IFN-γ) and CRP.
- Olucocorticoid resistance develops wherein cortisol does not as effectivity inhibit NF-κB activity, thus creating a pro-inflammatory allostatic state that can contribute to psychiatric symptoms via cytokine actions on glutamate, kynurenine, dopamine and serotonin systems in brain regions underlying emotion regulation and affect, including the striatum, dorsal anterior cingulate (dACC), medial prefrontal cortex (mPFC) and amygdala.

EVENTUAL INFLAMMATORY CHANGES


ALERT, SAFE, INTERESTED

Moderate levels of catecholamine release strengthen dIPFC, weaken amygdala, and reduce tonic LC firing (NE: α2A)



STRESS

High levels of catecholamine release weaken dIPFC, strengthen amygdala and striatum, and increase the tonic firing of the LC (NE: α 1, β 1)






LOOKING AT TREATMENT



TREATMENT CONSIDERATIONS FROM GUT TO BRAIN

- Look at the causation first and remove if you can i.e., alcoholism
- Dietary and lifestyle considerations
- Eradicate causation (Medication / herbal)
- Removal of toxins
- Break down food: Enzymes Bile HCL SCFA
- Restore the lining and reduce inflammation
- Support appropriate prebiotics and probiotics
- Motility support
- Barrier support
- Transmitter support
- BDNF support
- Vagal support
- Visceral massage
- Brain-based exercises
- Understand the presence of antibodies in the gut and brain to determine long-term care
- Look for other environmental perpetuators



NO DISCLOSURES

Statement of Intended Use/Disclaimers

All information, data, and material contained, presented, or provided in this program (each slide) / presentation ("Information") is for general information purposes only and solely the opinion of the authors and presenters. The information should not be construed or intended as providing personalized medical or legal advice.

The Information is not necessarily considered mainstream health care but is relatively supportive of an individual's physiology for optimal health. It is left to the discretion and judgment of each individual obtaining this data to use it appropriately. It is the sole responsibility of the recipient of the Information provided to determine if the products, procedures, treatments, tests, and therapies described are appropriate for the client and within their scope of practice.

Neither the speaker nor supporting companies can be held responsible for the information, opinions, or any inadvertent errors or omissions in the preparation or presentation of the Information given in this lecture. The information should not be construed as a claim regarding any procedure, treatment, therapy, test, or product beyond the given research provided to the public.

It is the sole responsibility of the recipient of this Information to comply with local laws regarding the use of such Information as it relates to the scope and type of user's practice and what is medically necessary and reasonable or customary.

The Department of Health and Human Services is concerned that no nutritional supplement be used to replace established, conventional medical approaches, especially in cases of emergencies or serious or life-threatening diseases or conditions.

The speakers and represented sponsors share in this concern, as replacing conventional treatment with homeopathic and/or nutraceutical intervention, especially in severe cases, might deprive the client of necessary treatment, thereby causing harm and could also pose a significant legal liability for the healthcare professional involved.

Any nutritional product or procedure reported in this presentation is not intended to diagnose, treat, cure, or prevent disease, nor should it be misused for treatment based upon degree and defined scope of practice.